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T 
HE FACT that no known therapeut ic  regimen will prevent  reeur- 
fence of peptic ulcer or will heal peptic ulcers in all patients has 
led to the search for methods of the rapy  other than those directed 
at reduction or control of acidity. The possibility that eoating sub- 
stances might effectively prevent  acid peptic digestion of the 
mueosa has been considered, but up to the present  time no effective 
"eoat ino" '  substanee is available, lnvesti? 'ations initially earr ied 
out in animals showed that  silicone, which is sueh a "eoa t ing" '  sub- 
stance, would effectively prevent  ulcer ,  in pylorus-l igated rats  ~ 
suo'gested to us the possible use of silieone in peptic uleer in man. 
Suhsequent stmlie.s showed that  dog's reeeiving silicone by stomach 
tube seemed to be protected against  the format ion of histamine-in- 
dueed uleers. In addition, in dogs given silieone af ter  ulcers had 
been produced by daily his tamine administrat ion,  the histamine- 
induced uleers healed even though his tamine injections were eon- 
tim~ed.'-' In view of this we felt that  we were justified in evaluating 
silicone in patients with peptic ulcers. A long-term, double-blind 
trial was designed to compare the effeets of silieone with placebo 
therapy.  
E X P E R I M E N T A L  DESIGN 
Any patient of either sex and any age was admit ted  to the trial 
if he or she indicated willingness to a t tend regular ly  onee a month 
for 6 to 12 months on the following' medical indications:  
I. A definite diagnosis of ulcer must have been made, either 
gastroseopieally, radiologieally, or on indisputable elinieal grounds 
within the last t8 months. 
2. No patient  who had been symptom-free  for over 4 months 
was admit ted to the trial until, and unless, symptoms developed. 
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3. The members  of the Gastroenterology Clinic had complete- 
control of the pat ient ' s  therapy throughout  the tr ial  or the patient  
was dropped from evaluation. 
Both outpat ients  (chronic active ulcer) and inpatients (acute 
active ulcer) were admit ted  to the trial. Any patient  admit ted to 
the hospital  for medical  t rea tment  of the nicer was seen daily on 
ward  rounds, and all outpatients  were seen at least once every 
month and ninny of them at more f requent  intervals,  depending on 
the state of the pat ient ' s  symptoms. 
A 30 per cent silicone emulsion (Dow-Corning Corporation),* 
suitably flavored, and a physically similar prepara t ion  containing 
20 per cent a luminum hydroxide were furnished by Eli  Lilly and 
Company. I t  was found necessary to add the a luminum hydroxide 
to the placebo medicat ion in order  to provide a texture similar to 
that  of the silicone emulsion. The pat ients  gett ing the placebo 
prepara t ion  received the equivalent of 1 to 3 ee. of aluminmn 
hydroxide gel six times daily. We felt  that  this amount  was welt 
below the opt imum therapeut ic  one. Each  patient,  on admission to 
the trial, received a number  according to the random allocation of 
numbers  previously made. The number  was checked by the phar- 
macist  against  the master  list, a copy of which was held by the 
chief pharmacis t  so that  the pat ient  received the same mixture 
throughout  the trial. The bottles were  labeled with the pat ient ' s  
name and number  only, so that  at no time did the physician in 
charge of the ease know what  medicat ion the pat ient  was receiving. 
All pat ients  were  advised to eat three  meals daily with interval  
feedings and were told to take Bellarbital ,  (containing phenobar- 
bital 15 rag. and bel ladonna 16 nag.), one tablet 4 times daily. No 
other long-term or chronic medications were utilized in this study 
other than either the placebo or the silicone emulsion. 
The results were assessed on the following: (1) Relief of acute 
symptoms while in the hospital ;  (2) prevent ion of recurrence of 
pain;  and (3) prevent ion of complications such as hemorrhage,  
perforat ion,  and /or  the necessity for operation. The first objec- 
tive, the relief of acute symptoms, was established by day-to-day 
interview of the ulcer patients in the hospital,  noting the pat ients '  
description of pain in the previous 24 hours, the number  of tablets 
of antacid needed by the patient,  and complications occurring in 
*The si l icone was an an t i foam,  descr ibed in  the ea r ly  exper iments  1' 2 as XEC 151, and  
as shown in l a t e r  expe r imen t s  as 240-41-101. 
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the hospital. The prevcution of recurrences and complications was 
the major object of the regular monthly observations and inter- 
views in the outpatient department, where the following points 
were noted: (1) patient 's weight; (2) amount of pain complained 
of by the patient ; (3) complications, if any; and (4) status of bowel 
habits (the effects of silicone). 
R E S U L T S  
Table 1 summarizes the over-all results in patients treated with 
silicone and placebo, respectively, at 3-month intervals up to 1 year 
after starting treatment. Of the placebo group, 27 of 32 were 
" c u r e d "  at 3 months and 23 of 28 at 6 months (85 per cent and 
82 per cent, respectively). 
These high figures for improvement are the most important be- 
cause ulcer patients seen at the University Hospital are, in gen- 
eral, those who have been intractable on previous treatment. On 
questioning, practically all of these patients stated that they had 
taken Amphojel in the past, and had either not had satisfactory 
response to it or had become refractory to it. In spite of this and 
because they realized that they were being tried on a "new drug,"  
82 per cent of these patients previously refractory to Amphojel 
therapy were improved at the end of 6 months when given highly 
diluted Amphojel. In other words, it would seem that the thera- 
peutic effects of the patient 's  emotional response to a "new d rug"  
therapy was extremely great. I t  would seem on this basis that 
giving an ulcer patient anything that is not harmful to the patient 
could result in improvement in at least 80 per cent if followed for 
TABLE 1. Resu l t s  of  Si l icone and Placebo Treatment  in Patients  with  
D u o d e n a l  Ulcer 
3 Months 6 Months  9 Months  12 Months 
Placebo : S F S F S F S F 
l~1ales 24 5 20 5 16 8 10 13 
Females 3 0 3 0 2 1 1 1 
TOTAL 27 5 23 5 18 9 11 14 
Silicone: S F S F S F S F 
Males 20 10 16 12 13 14 10 16 
Females 3 1 1 3 1 3 1 3 
TOTAL 23 11 17 15 14 ]7 11 19 
S : Success of therapy to date. 
F ~ Fai lure  of therapy to date. 
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only 6 months. A snlaller proportion,  23 of 34 (68 per cent) pa- 
tients on silicone t reatment ,  were improved at  the end of 3 months. 
I t  is interest ing to note that as time went by at 6 months, 9 months, 
and finally at 12 months, the placebo and silicone groups tend to 
become more and more similar, so that  at the end of one year  only 
11 of 25 patients still being followed in the placebo group, or 44 
per cent, were tint)roved, and 11 of 30, or 37 1)er cent, were im- 
proved in the silicone group. 
DISCUSSION 
It is obvious that the silicone used in this study had no intrinsic 
therapeut ic  effectiveness ei ther in the relief of acute symptoms or 
in the prevention of recurrences  or complications of peptic ulcer 
disease, in fact, the over-all relapse ra te  was grea ter  over the 
whole s tudy (see Tables 1 and 2) (X 2 = 20.116; d/ = 9; p < .02). 
The fai lure of the silicone to remain  effective proml)ted a repeat  
check on the effectiveness in experimental  ulceration. As it turned 
out, the s tudy was actual ly conducted with two ineffective drugs, 
240-41-101, (the silicone) and 240-41-86 (the placebo)? It  thus was 
in effect a study of the natura l  h is tory  of chronic peptic ulceration 
under  close obsevvation wilh ils inevitable psychosomatic over- 
tones. 
The importance of an "emot iona l  eo fac to r "  in the t rea tment  of 
peptic ulcer is brought  out str ikingly by the fact that at 3 months 
77 per cent of the patients in both groups had 1)een relieved of their 
acute symptonls and had not had recurrences  and, at the end of 1 
year,  40 pet" cent of patients were still relieved of their  symI)toms 
and had not had sio'nificant recurrences.  Besides emphasizing the 
significance of the emotional cofaetors in the therapy  of peptic 
TABLE 2. 4 X 4 Contingency Table Conslructed from Data in Table 1 (Males and 
Females  C o m b i n e d ) ,  Showing  Signif icant  '~ Differences Between Treatments  4 
3 Months  6 Months  9 Months  12 Months  Tota l  
P lacebo  
Successful  1.240 .517 .075 2.848 4.680 
FMled  1.847 1.312 .125 5.389 8.673 
Sil icone 
Successful  1.453 .030 .205 1.066 2.754 
~ 'ai ied 2.176 .023 .266 ] .544 4.000 
TOTAL 6.716 1.882 .671 I 0.~47 20 . l l  6 
~df  ~ 9; X 2 ~ 20.116; p ~ .02 .  
1$8 
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ulcer, these resul ts  underscore  the absolute  necessi ty of ca r ry ing  
out double-blind studies of adequa te  dura t ion  before any con- 
clusions as to the the rapeu t ic  efficacy of any drug' ill the t r ea tmen t  
of peptic ulcer call be evaluated.  
SUMMARY and CONCLUSION 
In a controlled double-blind t r ia l  of the the rapeu t ic  effectiveness 
of silicone in pat ients  with  duodenal  ulcer, the silicone tes ted was 
shown to be sl ightly less effective than  placebo medicat ion.  The 
relatively good early response  of chronical ly r ecur r ing  ulcer dis- 
ease appea red  to be due to the emot ional  impact  of " a  new treat-  
ment  of u lcers . "  
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